Penn Medicine Provider
Medical Oncology
Daniel Lefler, MD
he/him
5.0
(133)
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital
View 1 additional location
Make an appointmentCall 800-789-7366

About me

  • Assistant Program Director, Hematology/Oncology Fellowship
  • Associate Clinical Director, Sarcoma Medical Oncology
  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: Cooper Medical School of Rowan University
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Thomas Jefferson University Hospital

What my patients think about me

Average Rating
5.0

133 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
superb doctor
May 2025
5.0
5.0
he is very knowledgeable affable and engaged
April 2025
5.0
5.0
trustworthy and caring + came highly recommended
April 2025
5.0
5.0
trust!

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Lefler is a Penn Medicine physician.

Qualifications and experience

My research

Daniel S Lefler, Andrew Elliott, Wei Jiang, Ubaldo Martinez-Outschoorn, Jude Al-Sabah, Daniel M Freed, Caitlin M King, Robert G Maki, Richard F Riedel, Jaime F Modiano, Daniel Hübschmann, Hanno Glimm, Stefan Fröhling, Matthew Oberley, Sosipatros A Boikos, Atrayee Basu Mallick Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma , JCO Precis Oncol, 9: 2025,e2500149.

Mohammad S Farooq, Neha Shafique, Gracia M Vargas, Jennifer Guo, John T Miura, Daniel S Lefler, Giorgos C Karakousis Neoadjuvant Immunotherapy for Resectable Dedifferentiated Liposarcoma: A National Cohort Analysis , J Surg Oncol, 131(8): 2025,1683-1691.

Gabriel Aleixo, Lee Hartner, Mark Diamond, Lazlo Nziga, Daniel Lefler Liposomal vs conventional doxorubicin as first-line therapy in advanced soft tissue sarcomas: A tertiary US center’s 8.5-year experience , The American Society of Clinical Oncology Annual Meeting, Chicago, IL.: 2025

Lefler, D.S., Maki, R.G., Somaiah, N., …Basu Mallick, A. Characterizing the genomic landscape of perivascular epithelioid cell family of tumors in a real-world patient population using the Foundation Medicine genomic database , Connective Tissue Oncology Society Annual Meeting, San Diego, CA.: 2024

Lefler, D.S., Moding, E.J., Basu Mallick, A mTOR activity: a biomarker for chemo- and immunotherapy response and outcomes in sarcomas , Connective Tissue Oncology Society Annual Meeting, San Diego, CA.: 2024

Lefler, D.S., Elliott, A., Blomain, E.S., …Basu Mallick, A Characterizing patterns of mTORC1 activation across sarcomas using single-sample gene set enrichment analysis (ssGSEA) and a national biomarker database , American Society of Clinical Oncology Annual Meeting, Chicago,IL: 2024

Jirka GW, Lefler DS, Russo J, Bashir B. Colon adenocarcinoma and Birt-Hogg-Dubé syndrome in a young patient: case report and exploration of pathologic implications , Cancer Biol Ther, 24(1): 2023,2184153

Lefler DS, Manobianco SA, Bashir B. Immunotherapy resistance in solid tumors: mechanisms and potential solutions , Cancer Biol Ther, 25(1): 2023,2315655

Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, Giri VN, Miller J, Maley W, Shah AP, DiMeglio M, Ambelil M, Yu R, Sato T, Lefler DS Liver Transplantation in a Woman with Mahvash Disease , N Engl J Med, 389(21): 2023,1972-1978

Lefler, D.S., Elliott, A., Maki, R.G., …Basu Mallick, A. Overexpression of cyclin dependent kinases and cyclins across sarcomas beyond CDK4 , Connective Tissue Oncology Society Annual Meeting, Dublin, Ireland : 2023